Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma.
| Title: | Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma. |
|---|---|
| Authors: | Barr PM; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.; Smith SD; University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Roschewski MJ; National Cancer Institute, Bethesda, MD, USA.; O'Brien SM; Chao Family Comprehensive Cancer Center, University of California-Irvine, Irvine, CA, USA.; Sharman JP; Willamette Valley Cancer Institute and Research Center, US Oncology Research, Eugene, OR, USA.; Melear JM; Texas Oncology, Austin, TX, USA.; Patel P; AstraZeneca, South San Francisco, CA, USA.; Calvo R; AstraZeneca, Gaithersburg, MD, USA.; Yang H; AstraZeneca, South San Francisco, CA, USA.; Spurgeon SE; Knight Cancer Institute, Oregon Health and Sciences University, Portland, OR, USA. |
| Source: | Leukemia & lymphoma [Leuk Lymphoma] 2022 Jul; Vol. 63 (7), pp. 1728-1732. Date of Electronic Publication: 2022 Feb 24. |
| Publication Type: | Clinical Trial, Phase I; Clinical Trial, Phase II; Letter; Research Support, Non-U.S. Gov't |
| Language: | English |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE |
| Imprint Name(s): | Publication: [Philadelphia, PA] : Taylor & Francis; Original Publication: Chur ; New York : London, UK : Harwood Academic Publishers ; Distributed by STBS, 1989- |
| MeSH Terms: | Lymphoma, B-Cell*/drug therapy ; Lymphoma, B-Cell*/pathology ; Phosphatidylinositol 3-Kinases*; Adenosine ; Benzamides ; Humans ; Pyrazines ; Quinolines |
| Substance Nomenclature: | K72T3FS567 (Adenosine); 0 (Benzamides); EC 2.7.1.- (Phosphatidylinositol 3-Kinases); 0 (Pyrazines); 0 (Quinolines); 19DG7G1U5Q (N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine); I42748ELQW (acalabrutinib) |
| Entry Date(s): | Date Created: 20220224 Date Completed: 20220712 Latest Revision: 20260127 |
| Update Code: | 20260130 |
| DOI: | 10.1080/10428194.2022.2043301 |
| PMID: | 35200084 |
| Database: | MEDLINE |
Clinical Trial, Phase I; Clinical Trial, Phase II; Letter; Research Support, Non-U.S. Gov't